Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S

The goal of this prospective cohort registration study is to establish an early warning system for futile recanalization in acute ischemic stroke by analyzing multi-omics information to identify key regulatory nodes and target molecules in ineffective recanalization.

The core issue addressed by this research is: Identifying key regulatory nodes and target molecules closely associated with futile recanalization, revealing the interactions among the neurovascular unit, peripheral immune cells, and the brain lymphatic system, as well as developing early diagnostic biomarkers and novel diagnostic technologies for futile recanalization.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Acute Ischemic Stroke (AIS) Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Endovascular Thrombectomy Ischemic Stroke Nervous System Diseases Neurovascular Unit- Brain Lymphatic System Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Luojun WANG

Xi’an, Shanxi, 710077, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent

Exclusion criteria

1. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival <6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up

Treatment and study plan

Primary outcomes

3-month mRS score

Time frame: From enrollment to the end of treatment at 3 months

Other outcomes

All-cause mortality within 3 months

Time frame: From enrollment to the end of treatment at 3months

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Collaborators

National Science and Technology Major Project

Registry information

Official study title

FUtile Reperfusion in acuTe iscHEmic stRoke- FURTHER

Important dates

Study start: 2025
Primary completion: 2028
Study completion: 2029
First posted: Jul 1, 2025
Registry last updated: Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting